




## **Supplementary Figures**








**Supplementary Figure 1.** Identification of BMDMs. (a) Flow cytometry was carried out to determine the purity of BMDMs. Specific markers CD11b and F4/80 were used. (b) Immunofluorescence staining of F4/80 to identify the BMDMs.




**Supplementary Figure 2.** IL-34 enhanced the expression of scavenger receptor CD36 in BMDMs. (a) Quantitative data of the protein expression of CD36, SR-A and LOX-1 for Fig. 2e were presented of three independent experiments. (b) Analysis of mRNA levels of SR-A and LOX-1 was carried out by real-time quantitative PCR. Data represent mean  $\pm$  SD of n = 3 biologically independent experiments. \*P< 0.05, \*\*P< 0.01.









**Supplementary Figure 3.** Uncropped images of Fig. 2e, 3b, 4a and 4c.

## **Supplementary Tables**

**Supplementary Table 1.** Sequence of Primers used in the present study.

RT-PCR	Forward	Reverse
CD36	AGGAATTTGTCCTATTGGGAAAGTT	CCGCAGTACCCGAGACTTCT
SR-A	GGGAACACTCACAGACACTGAAA	GGGTTGATCCGCCTACACTC
LOX-1	CAAGATGAAGCCTGCGAATGA	ACCTGGCGTAATTGTGTCCAC
ABCA1	ATAGCAGGCTCCAACCCTGAC	GGTACTGAAGCATGTTTCGATGTT
ABCG1	GGGATCAGAACAGTCGCCTG	CGAGGTCTCTCTTATAGTCAGCGTC
SR-B	TTTGGAGTGGTAGTAAAAAGGGC	TGACATCAGGGACTCAGAGTAG
IL-1β	GCCCATCCTCTGTGACTCA	AGGCCACAGGTATTTTGTCG
IL-6	TAGTCCTTCCTACCCCAATTTCC	TTGGTCCTTAGCCACTCCTTC
TNF-α	CCCTCACACTCAGATCATCTTCT	TGCTACGACGTGGGCTACAG
β-actin	TGCTGTCCCTGTATGCCTCTG	AGGGAGAGCGTAGCCCTCAT